Revance Therapeutics Inc (RVNC)
3.025
-0.14
(-4.27%)
USD |
NASDAQ |
May 17, 16:00
3.02
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Enterprise Value: 468.20M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 17, 2024 | 468.20M |
May 16, 2024 | 482.82M |
May 15, 2024 | 498.49M |
May 14, 2024 | 516.25M |
May 13, 2024 | 499.54M |
May 10, 2024 | 499.54M |
May 09, 2024 | 600.85M |
May 08, 2024 | 598.76M |
May 07, 2024 | 610.25M |
May 06, 2024 | 581.00M |
May 03, 2024 | 565.34M |
May 02, 2024 | 546.54M |
May 01, 2024 | 549.15M |
April 30, 2024 | 529.83M |
April 29, 2024 | 538.04M |
April 26, 2024 | 507.76M |
April 25, 2024 | 496.27M |
April 24, 2024 | 525.51M |
April 23, 2024 | 534.91M |
April 22, 2024 | 532.82M |
April 19, 2024 | 547.44M |
April 18, 2024 | 548.48M |
April 17, 2024 | 545.35M |
April 16, 2024 | 550.57M |
April 15, 2024 | 567.27M |
Date | Value |
---|---|
April 12, 2024 | 583.98M |
April 11, 2024 | 616.35M |
April 10, 2024 | 613.21M |
April 09, 2024 | 642.45M |
April 08, 2024 | 617.39M |
April 05, 2024 | 613.21M |
April 04, 2024 | 613.21M |
April 03, 2024 | 627.83M |
April 02, 2024 | 623.65M |
April 01, 2024 | 646.62M |
March 31, 2024 | 666.46M |
March 28, 2024 | 687.92M |
March 27, 2024 | 690.01M |
March 26, 2024 | 664.99M |
March 25, 2024 | 659.78M |
March 22, 2024 | 682.71M |
March 21, 2024 | 716.06M |
March 20, 2024 | 703.55M |
March 19, 2024 | 688.96M |
March 18, 2024 | 690.01M |
March 15, 2024 | 728.04M |
March 14, 2024 | 741.07M |
March 13, 2024 | 802.56M |
March 12, 2024 | 830.18M |
March 11, 2024 | 827.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
198.56M
Minimum
Jun 10 2019
3.267B
Maximum
May 09 2023
1.353B
Average
1.285B
Median
Enterprise Value Benchmarks
AbbVie Inc | 349.85B |
Eli Lilly and Co | 755.52B |
Aquestive Therapeutics Inc | 216.71M |
Humacyte Inc | 638.30M |
AN2 Therapeutics Inc | -46.50M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -53.15M |
Revenue (Quarterly) | 51.94M |
Total Expenses (Quarterly) | 98.76M |
EPS Diluted (Quarterly) | -0.58 |
Gross Profit Margin (Quarterly) | 71.29% |
Profit Margin (Quarterly) | -102.3% |
Earnings Yield | -120.5% |
Normalized Earnings Yield | -90.60 |